Immunotherapy effective for cancer patients with HIV

Immunotherapy -- specifically, checkpoint inhibitors -- are both safe and effective for HIV patients who are being treated for cancer, new research shows.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

Publication date: June 2019Source: Biomedicine &Pharmacotherapy, Volume 114Author(s): Xiwei Ji, Yuan Lu, Huifang Tian, Xiangrui Meng, Minji Wei, William C. ChoAbstractChemoresistance is one of the major challenges for the breast cancer treatment. Owing to its heterogeneous nature, the chemoresistance mechanisms of breast cancer are complicated, and not been fully elucidated. The existing treatments fall short of offering adequate solution to drug resistance, so more effective approaches are desperately needed to improve existing therapeutic regimens. To overcome this hurdle, a number of strategies are being investigate...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an... Author: cancergrace Added: 03/26/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Authors: Leduc C, Quoix E Abstract Antigen-specific immunotherapy also known as cancer vaccination offers a novel approach for the treatment of non-small cell lung cancer patients. It relies on specific priming of the immune system in order to provoke or increase adaptive antitumor immune response against the vaccine component. Several molecules have been developed in lung cancer, based on whole-tumor cells, dendritic cells, peptides, recombinant proteins, or viral vectors. The aim of this review is to describe the mechanism of action of these vaccines and the results of the main clinical studies. PMID: 3090244...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
CONCLUSIONS: Based on the availability of different formulations of CTA-based vaccines, future researches should compare efficiency of these modalities. PMID: 30909205 [PubMed - as supplied by publisher]
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
By BISHAL GYAWALI MD, PhD Hey, I’m back! Well, you might not have noticed that my blogs were missing for the last three months but anyways, its good to be back. I was having a little time off blogs and social media as I was transitioning in my career but now I am back. Sometimes, it is very difficult to manage time for things that you must do versus things you enjoy doing, especially when these two don’t intersect. For me, these last few months the things I had to do were all bureaucratic while I couldn’t find the time for things I enjoy doing like writing these blogs. But now that we are back,...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Bishal Gyawali Cancer drugs Clinical Trials Oncology Prostate Cancer RCTs Source Type: blogs
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy, Published online: 26 March 2019; doi:10.1038/s41571-019-0203-7The metabolic conditions in tumours can result in phenotypic reprogramming of non-tumour cells, including immune cells, in the tumour microenvironment. This Review provides an overview of the pathways of cancer metabolism that intersect with immunometabolism, typically resulting in immunosuppression, with a focus on how these metabolic pathways could be targeted in order to enhance anticancer immunity and immunotherapy.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research
Conditions:   Colorectal Liver Metastases;   Colorectal Cancer;   Liver Metastases;   Immunotherapy Intervention:   Procedure: Hepatectomy Sponsor:   Humanitas Clinical and Research Center Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PLYMOUTH MEETING, Pa., March 25, 2019 -- (Healthcare Sales &Marketing Network) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career la... Biopharmaceuticals, Oncology, Personnel Inovio Pharmaceuticals, immunotherapy, cancer vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for various cancers, filed with the SEC to raise up to $86 million in an initial public offering.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
Date: Wednesday, 04 17, 2019; Speaker: Thomas Gajewski, MD, PhD, Professor, Departments of Pathology, , Medicine, and the Ben May Institute and Program Leader, Immunology and Cancer , Program, University Chicago Comprehensive Cancer Center; Building: Building 10 (Clinical Center); Lipsett Amphitheater; CME Credit; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Cancer | Cancer & Oncology | Health | Immunotherapy